Indo Global Exchange(s) PTE, Ltd.

OTC: IGEX · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Jakarta, CIK 0001442853Reports USD

#1153 of 1,406 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH —DQ —GM —SS 48

v0.1 · 5/100 weight · pillars only

↑ listing tenure, growth stability · ↓ revenue growth (YoY), 3-yr revenue growth

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

Employees

—

Market cap

$2.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02017

Net income$0$02017

Total assets$0$02017

Liabilities$486.5k$486.5k2017

Equity-$486.5k-$486.5k2017

Revenue trend

FY2015 – FY2017 · USD

$10.7k

FY15

$19.4k

FY16

$3.5k

FY16

FY17

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Indo Global Exchange(s) PTE, Ltd. booked $0 in FY2017 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a NaN% net margin.

Peers · Healthcare

Ensysce Biosciences, Inc.31D Oragenics, Inc.46D Reliq Health Technologies Inc.——Vivos Therapeutics, Inc.38D

Key facts

CEOSergio Bellosta Suarez

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersJakarta, null

ExchangeOTC: IGEX

Employees—

IPO date2013-05-29

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.